Exercise4

Akari Therapeutics Plc

Total Value

$1.4M

Filing Date

Oct 16, 2026

1 transactions

Trade Summary

On Aug 18, 2026 through Oct 14, 2026, Gaslightwala Abizer, CEO, Director, reported $1.4M of Akari Therapeutics Plc (AKTX) across 1 transactions. The filing covers American Depositary Shares representing Ordinary Shares and reflects balanced net activity of $0. Reported prices ranged from $0.00 to $7.90. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.

Insider Information

Name: Gaslightwala Abizer
Role: CEO, Director
Location: TAMPA, FL

Filing Details

Filing Date: Oct 16, 2026
Transaction Date: Aug 18, 2026
Accession Number: 0001493152-26-047454
Form Type: 4

Non-Derivative Transactions

Date	Security	Shares	Price	Type	Value
Oct 14, 2026	American Depositary Shares representing Ordinary Shares	19,333	$0.00	Exercise	$8
Oct 14, 2026	American Depositary Shares representing Ordinary Shares	7,733	$0.00	Exercise	$3

Derivative Transactions

Date	Security	Shares	Exercise Price	Type	Value
Aug 18, 2026	AKTX derivative	174,000	$7.90	Grant/Award	$1.4M
Oct 14, 2026	AKTX derivative	19,333	$0.00	Exercise	$8
Oct 14, 2026	AKTX derivative	7,733	$0.00	Exercise	$3

Want live alerts when Gaslightwala Abizer trades again?

Download Insider Trades to track AKTX, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.

iOS App Android App

Footnotes

(F1)On August 18, 2026, the Reporting Person was granted an option to purchase 174,000 American Depository Shares ("ADSs"). This option grant is subject to forfeiture if shareholder approval of a proposed amendment to the Issuer's equity incentive plan to increase the number of shares reserved for issuance under the plan ("Shareholder Approval") is not obtained. Beginning on the date of Shareholder Approval, this option will vest with respect to 2.08% of the grant for each one-month anniversary from March 18, 2026 (the "Accrual Date") that has elapsed before the date of Shareholder Approval. The remainder of the option grant will vest in equal, monthly installments beginning on the 18th day of the month subsequent to the month where Shareholder Approval was obtained until fully vested on the four-year anniversary of the Accrual Date, subject to the Reporting Person's continued service with the Issuer on each such vesting date.
(F2)The pre-funded warrants became exercisable upon shareholder approval, which was obtained on March 2, 2026.
(F3)The pre-funded warrants remain exercisable until fully exercised.
(F4)On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) pre-funded warrants (the "Note Exchange Unregistered Pre-Funded Warrants") to purchase up to 19,333 ADSs, at a purchase price of $16.16 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) warrants to purchase up to 19,333 ADSs.
(F5)On December 16, 2025, the Reporting Person and the Issuer entered into a securities purchase agreement, pursuant to which the Issuer issued to the Reporting Person (i) pre-funded warrants (the "Private Placement Pre-Funded Warrants") to purchase up to 7,733 ADSs, at a purchase price of $16.16 per Private Placement Pre-Funded Warrant, and (ii) warrants to purchase up to 7,733 ADSs.
(F6)The combined purchase price per one pre-funded warrant and accompanying warrant was $16.16.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gaslightwala Abizer

(Last)

(First)

(Middle)

C/O AKARI THERAPEUTICS PLC

401 EAST JACKSON STREET, SUITE 3300

(Street)

TAMPA

33602

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Akari Therapeutics Plc [ AKTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CEO

3. Date of Earliest Transaction (Month/Day/Year)
08/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
American Depositary Shares representing Ordinary Shares	10/14/2026		M		19,333	A	$0.0004	33,440	D
American Depositary Shares representing Ordinary Shares	10/14/2026		M		7,733	A	$0.0004	41,173	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$7.899	08/18/2026		A		174,000		⁽¹⁾	08/18/2036	American Depositary Shares representing Ordinary Shares	174,000	$0	174,000	D
Pre-Funded Warrant to Purchase ADSs	$0.0004	10/14/2026		M			19,333	⁽²⁾	⁽³⁾	American Depositary Shares representing Ordinary Shares	19,333	$16.16⁽⁴⁾⁽⁶⁾	0	D
Pre-Funded Warrant to Purchase ADSs	$0.0004	10/14/2026		M			7,733	⁽²⁾	⁽³⁾	American Depositary Shares representing Ordinary Shares	7,733	$16.16⁽⁵⁾⁽⁶⁾	0	D

Explanation of Responses:

1. On August 18, 2026, the Reporting Person was granted an option to purchase 174,000 American Depository Shares ("ADSs"). This option grant is subject to forfeiture if shareholder approval of a proposed amendment to the Issuer's equity incentive plan to increase the number of shares reserved for issuance under the plan ("Shareholder Approval") is not obtained. Beginning on the date of Shareholder Approval, this option will vest with respect to 2.08% of the grant for each one-month anniversary from March 18, 2026 (the "Accrual Date") that has elapsed before the date of Shareholder Approval. The remainder of the option grant will vest in equal, monthly installments beginning on the 18th day of the month subsequent to the month where Shareholder Approval was obtained until fully vested on the four-year anniversary of the Accrual Date, subject to the Reporting Person's continued service with the Issuer on each such vesting date.

2. The pre-funded warrants became exercisable upon shareholder approval, which was obtained on March 2, 2026.

3. The pre-funded warrants remain exercisable until fully exercised.

4. On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) pre-funded warrants (the "Note Exchange Unregistered Pre-Funded Warrants") to purchase up to 19,333 ADSs, at a purchase price of $16.16 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) warrants to purchase up to 19,333 ADSs.

5. On December 16, 2025, the Reporting Person and the Issuer entered into a securities purchase agreement, pursuant to which the Issuer issued to the Reporting Person (i) pre-funded warrants (the "Private Placement Pre-Funded Warrants") to purchase up to 7,733 ADSs, at a purchase price of $16.16 per Private Placement Pre-Funded Warrant, and (ii) warrants to purchase up to 7,733 ADSs.

6. The combined purchase price per one pre-funded warrant and accompanying warrant was $16.16.

	/s/ Abizer Gaslightwala, as Attorney-in-Fact	10/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Form 4 as rendered by the SEC from accession 0001493152-26-047454.

Akari Therapeutics Plc

Trade Summary

Company Information

Insider Information

Filing Details

Non-Derivative Transactions

Derivative Transactions

Want live alerts when Gaslightwala Abizer trades again?

Footnotes

SEC Form 4

SEC Filing

SEC Form 4